Axsome Therapeutics Inc/ US05464T1043 /
| 2024-04-17 10:00:00 PM | Chg. +0.9000 | Volume | Bid10:00:02 AM | Ask10:00:02 AM | High | Low |
|---|---|---|---|---|---|---|
| 69.7100USD | +1.31% | 399,847 Turnover: 18.54 mill. |
60.0000Bid Size: 300 | 71.2900Ask Size: 1,000 | 70.7800 | 68.1600 |
GlobeNewswire
3:00 AM
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...
GlobeNewswire
04-15
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurolog...
GlobeNewswire
04-12
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...
GlobeNewswire
04-04
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...
GlobeNewswire
04-01
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating...
GlobeNewswire
03-26
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...
GlobeNewswire
03-25
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Nee...
GlobeNewswire
03-25
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narc...
GlobeNewswire
03-19
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depr...
GlobeNewswire
03-05
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
GlobeNewswire
02-20
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busines...
GlobeNewswire
01-23
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
GlobeNewswire
01-04
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anti...
GlobeNewswire
2023-12-11
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depr...
GlobeNewswire
2023-12-07
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
GlobeNewswire
2023-12-05
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investor...
GlobeNewswire
2023-11-29
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investor...
GlobeNewswire
2023-11-29
Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; Dec...
GlobeNewswire
2023-11-28
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to...
GlobeNewswire
2023-11-24
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors...
Newsfile Corp
2023-11-24
AXSM FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Inv...
GlobeNewswire
2023-11-22
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
GlobeNewswire
2023-11-21
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
